AAV-based gene therapy for muscle disease
Contact us to add description: email@example.com
Kate Therapeutics is developing adeno-associated virus (AAV)-based gene therapies to treat muscle and heart diseases. The current limitations with gene therapies include tissue-specific delivery, liver detargeting and gene regulation. Kate is applying their novel technology platforms to improve the safety and efficacy of AAV gene therapy: this includes their novel capsids that provide superior muscle and heart transduction compared to naturally occurring serotypes that are currently used in clinical trials. With these advances, Kate is establishing a pipeline of muscle and cardiac disease indications that can be addressed with their capsid and cargo technologies.
Scientist– Cardiovascular Drug Discovery, Gene The...
San Diego, US|40 days ago
Director, Human Resources
San Diego, US|41 days ago
Senior/Executive Director – Nonclinical Developmen...
San Diego, US|54 days ago